Medical Care
Global Alzheimer's Disease Blood Diagnostic Market Outlook, In‑Depth Analysis & Forecast to 2031
- Nov 18, 25
- ID: 577962
- Pages: 144
- Figures: 133
- Views: 11
Report Includes:
This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Alzheimer's Disease Blood Diagnostic market across value chain. It analyzes historical revenue data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.
Critical competitive intelligence profiles players—revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise Industry‑chain overview maps upstream, middlestream, and downstream distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
Quanterix
C2N Diagnostics
Sysmex
Quest Diagnostics
Roche Diagnostics
Eli Lilly and Company
Fujirebio
Amoneta Diagnostics
MagQu
Vazyme
KingMed Diagnostics
Anqun Bioengineering
Segment by Type
Amyloid Beta (Aβ)
Tau Proteins
Others
Segment by Application
Early Diagnosis
Clinical Research
Sales by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
India
Australia
Vietnam
Indonesia
Malaysia
Philippines
Singapore
Rest of Asia
Europe
Germany
U.K.
France
Italy
Spain
Benelux
Russia
Rest of Europe
Central and South America
Brazil
Argentina
Rest of South America
Middle East & Africa
GCC Countries
Egypt
Israel
South Africa
Rest of MEA
Chapter Outline
Chapter 1: Defines the Alzheimer's Disease Blood Diagnostic study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the player landscape—ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down market size by Type, by Application and country, profiles key players and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional market by Type, by Application and players, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies market size by Type, by Application, and region/country, profiles top players, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures market size by Type, by Application, and country, profiles top players, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates market size by Type, by Application, and country, profiles key players, and outlines investment prospects and market hurdles
Chapter 11: Profiles players in depth—details product specs, revenue, margins; Top-tier players 2024 sales breakdowns by Product type, by Application, by region SWOT analysis, and recent strategic developments.
Chapter 12: Industry chain—analyses upstream, cost drivers, plus downstream channels.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 14: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Alzheimer's Disease Blood Diagnostic market across value chain. It analyzes historical revenue data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.
Critical competitive intelligence profiles players—revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise Industry‑chain overview maps upstream, middlestream, and downstream distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
Quanterix
C2N Diagnostics
Sysmex
Quest Diagnostics
Roche Diagnostics
Eli Lilly and Company
Fujirebio
Amoneta Diagnostics
MagQu
Vazyme
KingMed Diagnostics
Anqun Bioengineering
Segment by Type
Amyloid Beta (Aβ)
Tau Proteins
Others
Segment by Application
Early Diagnosis
Clinical Research
Sales by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
India
Australia
Vietnam
Indonesia
Malaysia
Philippines
Singapore
Rest of Asia
Europe
Germany
U.K.
France
Italy
Spain
Benelux
Russia
Rest of Europe
Central and South America
Brazil
Argentina
Rest of South America
Middle East & Africa
GCC Countries
Egypt
Israel
South Africa
Rest of MEA
Chapter Outline
Chapter 1: Defines the Alzheimer's Disease Blood Diagnostic study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the player landscape—ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down market size by Type, by Application and country, profiles key players and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional market by Type, by Application and players, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies market size by Type, by Application, and region/country, profiles top players, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures market size by Type, by Application, and country, profiles top players, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates market size by Type, by Application, and country, profiles key players, and outlines investment prospects and market hurdles
Chapter 11: Profiles players in depth—details product specs, revenue, margins; Top-tier players 2024 sales breakdowns by Product type, by Application, by region SWOT analysis, and recent strategic developments.
Chapter 12: Industry chain—analyses upstream, cost drivers, plus downstream channels.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 14: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
1 Study Coverage
1.1 Introduction to Alzheimer's Disease Blood Diagnostic: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Alzheimer's Disease Blood Diagnostic Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Amyloid Beta (Aβ)
1.2.3 Tau Proteins
1.2.4 Others
1.3 Market Segmentation by Application
1.3.1 Global Alzheimer's Disease Blood Diagnostic Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Early Diagnosis
1.3.3 Clinical Research
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Alzheimer's Disease Blood Diagnostic Revenue Estimates and Forecasts 2020-2031
2.2 Global Alzheimer's Disease Blood Diagnostic Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020-2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends
3 Competition by Players
3.1 Global Alzheimer's Disease Blood Diagnostic Player Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2020-2025)
3.1.2 Global Key Player Revenue Ranking (2023 vs. 2024)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Player (2020 VS 2024)
3.2 Global Alzheimer's Disease Blood Diagnostic Companies Headquarters and Service Footprint
3.3 Main Product Type Market Size by Players
3.3.1 Amyloid Beta (Aβ) Market Size by Players
3.3.2 Tau Proteins Market Size by Players
3.3.3 Others Market Size by Players
3.4 Global Alzheimer's Disease Blood Diagnostic Market Concentration and Dynamics
3.4.1 Global Market Concentration (CR5 and HHI)
3.4.2 Entrant/Exit Impact Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Alzheimer's Disease Blood Diagnostic Revenue Trends by Type
4.1.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.1.2 Global Revenue Market Share by Type (2020-2031)
4.2 Key Product Attributes and Differentiation
4.3 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.3.1 High-Growth Niches and Adoption Drivers
4.3.2 Profitability Hotspots and Cost Drivers
4.3.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Alzheimer's Disease Blood Diagnostic Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.1.2 Revenue Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application
6 North America
6.1 North America Market Size (2020-2031)
6.2 North America Key Players Revenue in 2024
6.3 North America Alzheimer's Disease Blood Diagnostic Market Size by Type (2020-2031)
6.4 North America Alzheimer's Disease Blood Diagnostic Market Size by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Alzheimer's Disease Blood Diagnostic Market Size by Country
6.6.1 North America Revenue Trends by Country
6.6.2 US
6.6.3 Canada
6.6.4 Mexico
7 Europe
7.1 Europe Market Size (2020-2031)
7.2 Europe Key Players Revenue in 2024
7.3 Europe Alzheimer's Disease Blood Diagnostic Market Size by Type (2020-2031)
7.4 Europe Alzheimer's Disease Blood Diagnostic Market Size by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Alzheimer's Disease Blood Diagnostic Market Size by Country
7.6.1 Europe Revenue Trends by Country
7.6.2 Germany
7.6.3 France
7.6.4 U.K.
7.6.5 Italy
7.6.6 Russia
8 Asia-Pacific
8.1 Asia-Pacific Market Size (2020-2031)
8.2 Asia-Pacific Key Players Revenue in 2024
8.3 Asia-Pacific Alzheimer's Disease Blood Diagnostic Market Size by Type (2020-2031)
8.4 Asia-Pacific Alzheimer's Disease Blood Diagnostic Market Size by Application (2020-2031)
8.5 Asia-Pacific Growth Accelerators and Market Barriers
8.6 Asia-Pacific Alzheimer's Disease Blood Diagnostic Market Size by Region
8.6.1 Asia-Pacific Revenue Trends by Region
8.7 China
8.8 Japan
8.9 South Korea
8.10 Australia
8.11 India
8.12 Southeast Asia
8.12.1 Indonesia
8.12.2 Vietnam
8.12.3 Malaysia
8.12.4 Philippines
8.12.5 Singapore
9 Central and South America
9.1 Central and South America Market Size (2020-2031)
9.2 Central and South America Key Players Revenue in 2024
9.3 Central and South America Alzheimer's Disease Blood Diagnostic Market Size by Type (2020-2031)
9.4 Central and South America Alzheimer's Disease Blood Diagnostic Market Size by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Alzheimer's Disease Blood Diagnostic Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Market Size (2020-2031)
10.2 Middle East and Africa Key Players Revenue in 2024
10.3 Middle East and Africa Alzheimer's Disease Blood Diagnostic Market Size by Type (2020-2031)
10.4 Middle East and Africa Alzheimer's Disease Blood Diagnostic Market Size by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Alzheimer's Disease Blood Diagnostic Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Israel
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Quanterix
11.1.1 Quanterix Corporation Information
11.1.2 Quanterix Business Overview
11.1.3 Quanterix Alzheimer's Disease Blood Diagnostic Product Features and Attributes
11.1.4 Quanterix Alzheimer's Disease Blood Diagnostic Revenue and Gross Margin (2020-2025)
11.1.5 Quanterix Alzheimer's Disease Blood Diagnostic Revenue by Product in 2024
11.1.6 Quanterix Alzheimer's Disease Blood Diagnostic Revenue by Application in 2024
11.1.7 Quanterix Alzheimer's Disease Blood Diagnostic Revenue by Geographic Area in 2024
11.1.8 Quanterix Alzheimer's Disease Blood Diagnostic SWOT Analysis
11.1.9 Quanterix Recent Developments
11.2 C2N Diagnostics
11.2.1 C2N Diagnostics Corporation Information
11.2.2 C2N Diagnostics Business Overview
11.2.3 C2N Diagnostics Alzheimer's Disease Blood Diagnostic Product Features and Attributes
11.2.4 C2N Diagnostics Alzheimer's Disease Blood Diagnostic Revenue and Gross Margin (2020-2025)
11.2.5 C2N Diagnostics Alzheimer's Disease Blood Diagnostic Revenue by Product in 2024
11.2.6 C2N Diagnostics Alzheimer's Disease Blood Diagnostic Revenue by Application in 2024
11.2.7 C2N Diagnostics Alzheimer's Disease Blood Diagnostic Revenue by Geographic Area in 2024
11.2.8 C2N Diagnostics Alzheimer's Disease Blood Diagnostic SWOT Analysis
11.2.9 C2N Diagnostics Recent Developments
11.3 Sysmex
11.3.1 Sysmex Corporation Information
11.3.2 Sysmex Business Overview
11.3.3 Sysmex Alzheimer's Disease Blood Diagnostic Product Features and Attributes
11.3.4 Sysmex Alzheimer's Disease Blood Diagnostic Revenue and Gross Margin (2020-2025)
11.3.5 Sysmex Alzheimer's Disease Blood Diagnostic Revenue by Product in 2024
11.3.6 Sysmex Alzheimer's Disease Blood Diagnostic Revenue by Application in 2024
11.3.7 Sysmex Alzheimer's Disease Blood Diagnostic Revenue by Geographic Area in 2024
11.3.8 Sysmex Alzheimer's Disease Blood Diagnostic SWOT Analysis
11.3.9 Sysmex Recent Developments
11.4 Quest Diagnostics
11.4.1 Quest Diagnostics Corporation Information
11.4.2 Quest Diagnostics Business Overview
11.4.3 Quest Diagnostics Alzheimer's Disease Blood Diagnostic Product Features and Attributes
11.4.4 Quest Diagnostics Alzheimer's Disease Blood Diagnostic Revenue and Gross Margin (2020-2025)
11.4.5 Quest Diagnostics Alzheimer's Disease Blood Diagnostic Revenue by Product in 2024
11.4.6 Quest Diagnostics Alzheimer's Disease Blood Diagnostic Revenue by Application in 2024
11.4.7 Quest Diagnostics Alzheimer's Disease Blood Diagnostic Revenue by Geographic Area in 2024
11.4.8 Quest Diagnostics Alzheimer's Disease Blood Diagnostic SWOT Analysis
11.4.9 Quest Diagnostics Recent Developments
11.5 Roche Diagnostics
11.5.1 Roche Diagnostics Corporation Information
11.5.2 Roche Diagnostics Business Overview
11.5.3 Roche Diagnostics Alzheimer's Disease Blood Diagnostic Product Features and Attributes
11.5.4 Roche Diagnostics Alzheimer's Disease Blood Diagnostic Revenue and Gross Margin (2020-2025)
11.5.5 Roche Diagnostics Alzheimer's Disease Blood Diagnostic Revenue by Product in 2024
11.5.6 Roche Diagnostics Alzheimer's Disease Blood Diagnostic Revenue by Application in 2024
11.5.7 Roche Diagnostics Alzheimer's Disease Blood Diagnostic Revenue by Geographic Area in 2024
11.5.8 Roche Diagnostics Alzheimer's Disease Blood Diagnostic SWOT Analysis
11.5.9 Roche Diagnostics Recent Developments
11.6 Eli Lilly and Company
11.6.1 Eli Lilly and Company Corporation Information
11.6.2 Eli Lilly and Company Business Overview
11.6.3 Eli Lilly and Company Alzheimer's Disease Blood Diagnostic Product Features and Attributes
11.6.4 Eli Lilly and Company Alzheimer's Disease Blood Diagnostic Revenue and Gross Margin (2020-2025)
11.6.5 Eli Lilly and Company Recent Developments
11.7 Fujirebio
11.7.1 Fujirebio Corporation Information
11.7.2 Fujirebio Business Overview
11.7.3 Fujirebio Alzheimer's Disease Blood Diagnostic Product Features and Attributes
11.7.4 Fujirebio Alzheimer's Disease Blood Diagnostic Revenue and Gross Margin (2020-2025)
11.7.5 Fujirebio Recent Developments
11.8 Amoneta Diagnostics
11.8.1 Amoneta Diagnostics Corporation Information
11.8.2 Amoneta Diagnostics Business Overview
11.8.3 Amoneta Diagnostics Alzheimer's Disease Blood Diagnostic Product Features and Attributes
11.8.4 Amoneta Diagnostics Alzheimer's Disease Blood Diagnostic Revenue and Gross Margin (2020-2025)
11.8.5 Amoneta Diagnostics Recent Developments
11.9 MagQu
11.9.1 MagQu Corporation Information
11.9.2 MagQu Business Overview
11.9.3 MagQu Alzheimer's Disease Blood Diagnostic Product Features and Attributes
11.9.4 MagQu Alzheimer's Disease Blood Diagnostic Revenue and Gross Margin (2020-2025)
11.9.5 MagQu Recent Developments
11.10 Vazyme
11.10.1 Vazyme Corporation Information
11.10.2 Vazyme Business Overview
11.10.3 Vazyme Alzheimer's Disease Blood Diagnostic Product Features and Attributes
11.10.4 Vazyme Alzheimer's Disease Blood Diagnostic Revenue and Gross Margin (2020-2025)
11.10.5 Company Ten Recent Developments
11.11 KingMed Diagnostics
11.11.1 KingMed Diagnostics Corporation Information
11.11.2 KingMed Diagnostics Business Overview
11.11.3 KingMed Diagnostics Alzheimer's Disease Blood Diagnostic Product Features and Attributes
11.11.4 KingMed Diagnostics Alzheimer's Disease Blood Diagnostic Revenue and Gross Margin (2020-2025)
11.11.5 KingMed Diagnostics Recent Developments
11.12 Anqun Bioengineering
11.12.1 Anqun Bioengineering Corporation Information
11.12.2 Anqun Bioengineering Business Overview
11.12.3 Anqun Bioengineering Alzheimer's Disease Blood Diagnostic Product Features and Attributes
11.12.4 Anqun Bioengineering Alzheimer's Disease Blood Diagnostic Revenue and Gross Margin (2020-2025)
11.12.5 Anqun Bioengineering Recent Developments
12 Alzheimer's Disease Blood DiagnosticIndustry Chain Analysis
12.1 Alzheimer's Disease Blood Diagnostic Industry Chain
12.2 Upstream Analysis
12.2.1 Upstream Key Suppliers
12.3 Middlestream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Alzheimer's Disease Blood Diagnostic Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Alzheimer's Disease Blood Diagnostic Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
1.1 Introduction to Alzheimer's Disease Blood Diagnostic: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Alzheimer's Disease Blood Diagnostic Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Amyloid Beta (Aβ)
1.2.3 Tau Proteins
1.2.4 Others
1.3 Market Segmentation by Application
1.3.1 Global Alzheimer's Disease Blood Diagnostic Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Early Diagnosis
1.3.3 Clinical Research
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Alzheimer's Disease Blood Diagnostic Revenue Estimates and Forecasts 2020-2031
2.2 Global Alzheimer's Disease Blood Diagnostic Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020-2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends
3 Competition by Players
3.1 Global Alzheimer's Disease Blood Diagnostic Player Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2020-2025)
3.1.2 Global Key Player Revenue Ranking (2023 vs. 2024)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Player (2020 VS 2024)
3.2 Global Alzheimer's Disease Blood Diagnostic Companies Headquarters and Service Footprint
3.3 Main Product Type Market Size by Players
3.3.1 Amyloid Beta (Aβ) Market Size by Players
3.3.2 Tau Proteins Market Size by Players
3.3.3 Others Market Size by Players
3.4 Global Alzheimer's Disease Blood Diagnostic Market Concentration and Dynamics
3.4.1 Global Market Concentration (CR5 and HHI)
3.4.2 Entrant/Exit Impact Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Alzheimer's Disease Blood Diagnostic Revenue Trends by Type
4.1.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.1.2 Global Revenue Market Share by Type (2020-2031)
4.2 Key Product Attributes and Differentiation
4.3 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.3.1 High-Growth Niches and Adoption Drivers
4.3.2 Profitability Hotspots and Cost Drivers
4.3.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Alzheimer's Disease Blood Diagnostic Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.1.2 Revenue Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application
6 North America
6.1 North America Market Size (2020-2031)
6.2 North America Key Players Revenue in 2024
6.3 North America Alzheimer's Disease Blood Diagnostic Market Size by Type (2020-2031)
6.4 North America Alzheimer's Disease Blood Diagnostic Market Size by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Alzheimer's Disease Blood Diagnostic Market Size by Country
6.6.1 North America Revenue Trends by Country
6.6.2 US
6.6.3 Canada
6.6.4 Mexico
7 Europe
7.1 Europe Market Size (2020-2031)
7.2 Europe Key Players Revenue in 2024
7.3 Europe Alzheimer's Disease Blood Diagnostic Market Size by Type (2020-2031)
7.4 Europe Alzheimer's Disease Blood Diagnostic Market Size by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Alzheimer's Disease Blood Diagnostic Market Size by Country
7.6.1 Europe Revenue Trends by Country
7.6.2 Germany
7.6.3 France
7.6.4 U.K.
7.6.5 Italy
7.6.6 Russia
8 Asia-Pacific
8.1 Asia-Pacific Market Size (2020-2031)
8.2 Asia-Pacific Key Players Revenue in 2024
8.3 Asia-Pacific Alzheimer's Disease Blood Diagnostic Market Size by Type (2020-2031)
8.4 Asia-Pacific Alzheimer's Disease Blood Diagnostic Market Size by Application (2020-2031)
8.5 Asia-Pacific Growth Accelerators and Market Barriers
8.6 Asia-Pacific Alzheimer's Disease Blood Diagnostic Market Size by Region
8.6.1 Asia-Pacific Revenue Trends by Region
8.7 China
8.8 Japan
8.9 South Korea
8.10 Australia
8.11 India
8.12 Southeast Asia
8.12.1 Indonesia
8.12.2 Vietnam
8.12.3 Malaysia
8.12.4 Philippines
8.12.5 Singapore
9 Central and South America
9.1 Central and South America Market Size (2020-2031)
9.2 Central and South America Key Players Revenue in 2024
9.3 Central and South America Alzheimer's Disease Blood Diagnostic Market Size by Type (2020-2031)
9.4 Central and South America Alzheimer's Disease Blood Diagnostic Market Size by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Alzheimer's Disease Blood Diagnostic Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Market Size (2020-2031)
10.2 Middle East and Africa Key Players Revenue in 2024
10.3 Middle East and Africa Alzheimer's Disease Blood Diagnostic Market Size by Type (2020-2031)
10.4 Middle East and Africa Alzheimer's Disease Blood Diagnostic Market Size by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Alzheimer's Disease Blood Diagnostic Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Israel
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Quanterix
11.1.1 Quanterix Corporation Information
11.1.2 Quanterix Business Overview
11.1.3 Quanterix Alzheimer's Disease Blood Diagnostic Product Features and Attributes
11.1.4 Quanterix Alzheimer's Disease Blood Diagnostic Revenue and Gross Margin (2020-2025)
11.1.5 Quanterix Alzheimer's Disease Blood Diagnostic Revenue by Product in 2024
11.1.6 Quanterix Alzheimer's Disease Blood Diagnostic Revenue by Application in 2024
11.1.7 Quanterix Alzheimer's Disease Blood Diagnostic Revenue by Geographic Area in 2024
11.1.8 Quanterix Alzheimer's Disease Blood Diagnostic SWOT Analysis
11.1.9 Quanterix Recent Developments
11.2 C2N Diagnostics
11.2.1 C2N Diagnostics Corporation Information
11.2.2 C2N Diagnostics Business Overview
11.2.3 C2N Diagnostics Alzheimer's Disease Blood Diagnostic Product Features and Attributes
11.2.4 C2N Diagnostics Alzheimer's Disease Blood Diagnostic Revenue and Gross Margin (2020-2025)
11.2.5 C2N Diagnostics Alzheimer's Disease Blood Diagnostic Revenue by Product in 2024
11.2.6 C2N Diagnostics Alzheimer's Disease Blood Diagnostic Revenue by Application in 2024
11.2.7 C2N Diagnostics Alzheimer's Disease Blood Diagnostic Revenue by Geographic Area in 2024
11.2.8 C2N Diagnostics Alzheimer's Disease Blood Diagnostic SWOT Analysis
11.2.9 C2N Diagnostics Recent Developments
11.3 Sysmex
11.3.1 Sysmex Corporation Information
11.3.2 Sysmex Business Overview
11.3.3 Sysmex Alzheimer's Disease Blood Diagnostic Product Features and Attributes
11.3.4 Sysmex Alzheimer's Disease Blood Diagnostic Revenue and Gross Margin (2020-2025)
11.3.5 Sysmex Alzheimer's Disease Blood Diagnostic Revenue by Product in 2024
11.3.6 Sysmex Alzheimer's Disease Blood Diagnostic Revenue by Application in 2024
11.3.7 Sysmex Alzheimer's Disease Blood Diagnostic Revenue by Geographic Area in 2024
11.3.8 Sysmex Alzheimer's Disease Blood Diagnostic SWOT Analysis
11.3.9 Sysmex Recent Developments
11.4 Quest Diagnostics
11.4.1 Quest Diagnostics Corporation Information
11.4.2 Quest Diagnostics Business Overview
11.4.3 Quest Diagnostics Alzheimer's Disease Blood Diagnostic Product Features and Attributes
11.4.4 Quest Diagnostics Alzheimer's Disease Blood Diagnostic Revenue and Gross Margin (2020-2025)
11.4.5 Quest Diagnostics Alzheimer's Disease Blood Diagnostic Revenue by Product in 2024
11.4.6 Quest Diagnostics Alzheimer's Disease Blood Diagnostic Revenue by Application in 2024
11.4.7 Quest Diagnostics Alzheimer's Disease Blood Diagnostic Revenue by Geographic Area in 2024
11.4.8 Quest Diagnostics Alzheimer's Disease Blood Diagnostic SWOT Analysis
11.4.9 Quest Diagnostics Recent Developments
11.5 Roche Diagnostics
11.5.1 Roche Diagnostics Corporation Information
11.5.2 Roche Diagnostics Business Overview
11.5.3 Roche Diagnostics Alzheimer's Disease Blood Diagnostic Product Features and Attributes
11.5.4 Roche Diagnostics Alzheimer's Disease Blood Diagnostic Revenue and Gross Margin (2020-2025)
11.5.5 Roche Diagnostics Alzheimer's Disease Blood Diagnostic Revenue by Product in 2024
11.5.6 Roche Diagnostics Alzheimer's Disease Blood Diagnostic Revenue by Application in 2024
11.5.7 Roche Diagnostics Alzheimer's Disease Blood Diagnostic Revenue by Geographic Area in 2024
11.5.8 Roche Diagnostics Alzheimer's Disease Blood Diagnostic SWOT Analysis
11.5.9 Roche Diagnostics Recent Developments
11.6 Eli Lilly and Company
11.6.1 Eli Lilly and Company Corporation Information
11.6.2 Eli Lilly and Company Business Overview
11.6.3 Eli Lilly and Company Alzheimer's Disease Blood Diagnostic Product Features and Attributes
11.6.4 Eli Lilly and Company Alzheimer's Disease Blood Diagnostic Revenue and Gross Margin (2020-2025)
11.6.5 Eli Lilly and Company Recent Developments
11.7 Fujirebio
11.7.1 Fujirebio Corporation Information
11.7.2 Fujirebio Business Overview
11.7.3 Fujirebio Alzheimer's Disease Blood Diagnostic Product Features and Attributes
11.7.4 Fujirebio Alzheimer's Disease Blood Diagnostic Revenue and Gross Margin (2020-2025)
11.7.5 Fujirebio Recent Developments
11.8 Amoneta Diagnostics
11.8.1 Amoneta Diagnostics Corporation Information
11.8.2 Amoneta Diagnostics Business Overview
11.8.3 Amoneta Diagnostics Alzheimer's Disease Blood Diagnostic Product Features and Attributes
11.8.4 Amoneta Diagnostics Alzheimer's Disease Blood Diagnostic Revenue and Gross Margin (2020-2025)
11.8.5 Amoneta Diagnostics Recent Developments
11.9 MagQu
11.9.1 MagQu Corporation Information
11.9.2 MagQu Business Overview
11.9.3 MagQu Alzheimer's Disease Blood Diagnostic Product Features and Attributes
11.9.4 MagQu Alzheimer's Disease Blood Diagnostic Revenue and Gross Margin (2020-2025)
11.9.5 MagQu Recent Developments
11.10 Vazyme
11.10.1 Vazyme Corporation Information
11.10.2 Vazyme Business Overview
11.10.3 Vazyme Alzheimer's Disease Blood Diagnostic Product Features and Attributes
11.10.4 Vazyme Alzheimer's Disease Blood Diagnostic Revenue and Gross Margin (2020-2025)
11.10.5 Company Ten Recent Developments
11.11 KingMed Diagnostics
11.11.1 KingMed Diagnostics Corporation Information
11.11.2 KingMed Diagnostics Business Overview
11.11.3 KingMed Diagnostics Alzheimer's Disease Blood Diagnostic Product Features and Attributes
11.11.4 KingMed Diagnostics Alzheimer's Disease Blood Diagnostic Revenue and Gross Margin (2020-2025)
11.11.5 KingMed Diagnostics Recent Developments
11.12 Anqun Bioengineering
11.12.1 Anqun Bioengineering Corporation Information
11.12.2 Anqun Bioengineering Business Overview
11.12.3 Anqun Bioengineering Alzheimer's Disease Blood Diagnostic Product Features and Attributes
11.12.4 Anqun Bioengineering Alzheimer's Disease Blood Diagnostic Revenue and Gross Margin (2020-2025)
11.12.5 Anqun Bioengineering Recent Developments
12 Alzheimer's Disease Blood DiagnosticIndustry Chain Analysis
12.1 Alzheimer's Disease Blood Diagnostic Industry Chain
12.2 Upstream Analysis
12.2.1 Upstream Key Suppliers
12.3 Middlestream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Alzheimer's Disease Blood Diagnostic Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Alzheimer's Disease Blood Diagnostic Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
List of Tables
Table 1. Global Alzheimer's Disease Blood Diagnostic Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Alzheimer's Disease Blood Diagnostic Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Alzheimer's Disease Blood Diagnostic Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Alzheimer's Disease Blood Diagnostic Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Alzheimer's Disease Blood Diagnostic Revenue by Region (2026-2031) & (US$ Million)
Table 6. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 7. Global Alzheimer's Disease Blood Diagnostic Revenue by Players (2020-2025) & (US$ Million)
Table 8. Global Alzheimer's Disease Blood Diagnostic Revenue Market Share by Players (2020-2025)
Table 9. Global Key Players’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 10. Global Alzheimer's Disease Blood Diagnostic by Player Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Alzheimer's Disease Blood Diagnostic as of 2024)
Table 11. Global Alzheimer's Disease Blood Diagnostic Average Gross Margin (%) by Player (2020 VS 2024)
Table 12. Global Alzheimer's Disease Blood Diagnostic Companies Headquarters
Table 13. Global Alzheimer's Disease Blood Diagnostic Market Concentration Ratio (CR5 and HHI)
Table 14. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 15. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 16. Global Alzheimer's Disease Blood Diagnostic Revenue by Type (2020-2025) & (US$ Million)
Table 17. Global Alzheimer's Disease Blood Diagnostic Revenue by Type (2026-2031) & (US$ Million)
Table 18. Key Product Attributes and Differentiation
Table 19. Global Alzheimer's Disease Blood Diagnostic Revenue by Application (2020-2025) & (US$ Million)
Table 20. Global Alzheimer's Disease Blood Diagnostic Revenue by Application (2026-2031) & (US$ Million)
Table 21. Alzheimer's Disease Blood Diagnostic High-Growth Sectors Demand CAGR (2024-2031)
Table 22. Top Customers by Region
Table 23. Top Customers by Application
Table 24. North America Alzheimer's Disease Blood Diagnostic Growth Accelerators and Market Barriers
Table 25. North America Alzheimer's Disease Blood Diagnostic Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 26. Europe Alzheimer's Disease Blood Diagnostic Growth Accelerators and Market Barriers
Table 27. Europe Alzheimer's Disease Blood Diagnostic Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 28. Asia-Pacific Alzheimer's Disease Blood Diagnostic Growth Accelerators and Market Barriers
Table 29. Asia-Pacific Alzheimer's Disease Blood Diagnostic Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 30. Central and South America Alzheimer's Disease Blood Diagnostic Investment Opportunities and Key Challenges
Table 31. Central and South America Alzheimer's Disease Blood Diagnostic Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 32. Middle East and Africa Alzheimer's Disease Blood Diagnostic Investment Opportunities and Key Challenges
Table 33. Middle East and Africa Alzheimer's Disease Blood Diagnostic Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 34. Quanterix Corporation Information
Table 35. Quanterix Description and Major Businesses
Table 36. Quanterix Product Features and Attributes
Table 37. Quanterix Revenue (US$ Million) and Gross Margin (2020-2025)
Table 38. Quanterix Revenue Proportion by Product in 2024
Table 39. Quanterix Revenue Proportion by Application in 2024
Table 40. Quanterix Revenue Proportion by Geographic Area in 2024
Table 41. Quanterix Alzheimer's Disease Blood Diagnostic SWOT Analysis
Table 42. Quanterix Recent Developments
Table 43. C2N Diagnostics Corporation Information
Table 44. C2N Diagnostics Description and Major Businesses
Table 45. C2N Diagnostics Product Features and Attributes
Table 46. C2N Diagnostics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 47. C2N Diagnostics Revenue Proportion by Product in 2024
Table 48. C2N Diagnostics Revenue Proportion by Application in 2024
Table 49. C2N Diagnostics Revenue Proportion by Geographic Area in 2024
Table 50. C2N Diagnostics Alzheimer's Disease Blood Diagnostic SWOT Analysis
Table 51. C2N Diagnostics Recent Developments
Table 52. Sysmex Corporation Information
Table 53. Sysmex Description and Major Businesses
Table 54. Sysmex Product Features and Attributes
Table 55. Sysmex Revenue (US$ Million) and Gross Margin (2020-2025)
Table 56. Sysmex Revenue Proportion by Product in 2024
Table 57. Sysmex Revenue Proportion by Application in 2024
Table 58. Sysmex Revenue Proportion by Geographic Area in 2024
Table 59. Sysmex Alzheimer's Disease Blood Diagnostic SWOT Analysis
Table 60. Sysmex Recent Developments
Table 61. Quest Diagnostics Corporation Information
Table 62. Quest Diagnostics Description and Major Businesses
Table 63. Quest Diagnostics Product Features and Attributes
Table 64. Quest Diagnostics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 65. Quest Diagnostics Revenue Proportion by Product in 2024
Table 66. Quest Diagnostics Revenue Proportion by Application in 2024
Table 67. Quest Diagnostics Revenue Proportion by Geographic Area in 2024
Table 68. Quest Diagnostics Alzheimer's Disease Blood Diagnostic SWOT Analysis
Table 69. Quest Diagnostics Recent Developments
Table 70. Roche Diagnostics Corporation Information
Table 71. Roche Diagnostics Description and Major Businesses
Table 72. Roche Diagnostics Product Features and Attributes
Table 73. Roche Diagnostics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 74. Roche Diagnostics Revenue Proportion by Product in 2024
Table 75. Roche Diagnostics Revenue Proportion by Application in 2024
Table 76. Roche Diagnostics Revenue Proportion by Geographic Area in 2024
Table 77. Roche Diagnostics Alzheimer's Disease Blood Diagnostic SWOT Analysis
Table 78. Roche Diagnostics Recent Developments
Table 79. Eli Lilly and Company Corporation Information
Table 80. Eli Lilly and Company Description and Major Businesses
Table 81. Eli Lilly and Company Product Features and Attributes
Table 82. Eli Lilly and Company Revenue (US$ Million) and Gross Margin (2020-2025)
Table 83. Eli Lilly and Company Recent Developments
Table 84. Fujirebio Corporation Information
Table 85. Fujirebio Description and Major Businesses
Table 86. Fujirebio Product Features and Attributes
Table 87. Fujirebio Revenue (US$ Million) and Gross Margin (2020-2025)
Table 88. Fujirebio Recent Developments
Table 89. Amoneta Diagnostics Corporation Information
Table 90. Amoneta Diagnostics Description and Major Businesses
Table 91. Amoneta Diagnostics Product Features and Attributes
Table 92. Amoneta Diagnostics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 93. Amoneta Diagnostics Recent Developments
Table 94. MagQu Corporation Information
Table 95. MagQu Description and Major Businesses
Table 96. MagQu Product Features and Attributes
Table 97. MagQu Revenue (US$ Million) and Gross Margin (2020-2025)
Table 98. MagQu Recent Developments
Table 99. Vazyme Corporation Information
Table 100. Vazyme Description and Major Businesses
Table 101. Vazyme Product Features and Attributes
Table 102. Vazyme Revenue (US$ Million) and Gross Margin (2020-2025)
Table 103. Vazyme Recent Developments
Table 104. KingMed Diagnostics Corporation Information
Table 105. KingMed Diagnostics Description and Major Businesses
Table 106. KingMed Diagnostics Product Features and Attributes
Table 107. KingMed Diagnostics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 108. KingMed Diagnostics Recent Developments
Table 109. Anqun Bioengineering Corporation Information
Table 110. Anqun Bioengineering Description and Major Businesses
Table 111. Anqun Bioengineering Product Features and Attributes
Table 112. Anqun Bioengineering Revenue (US$ Million) and Gross Margin (2020-2025)
Table 113. Anqun Bioengineering Recent Developments
Table 114. Raw Materials Key Suppliers
Table 115. Distributors List
Table 116. Market Trends and Market Evolution
Table 117. Market Drivers and Opportunities
Table 118. Market Challenges, Risks, and Restraints
Table 119. Research Programs/Design for This Report
Table 120. Key Data Information from Secondary Sources
Table 121. Key Data Information from Primary Sources
List of Figures
Figure 1. Alzheimer's Disease Blood Diagnostic Product Picture
Figure 2. Global Alzheimer's Disease Blood Diagnostic Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Amyloid Beta (Aβ) Product Picture
Figure 4. Tau Proteins Product Picture
Figure 5. Others Product Picture
Figure 6. Global Alzheimer's Disease Blood Diagnostic Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 7. Early Diagnosis
Figure 8. Clinical Research
Figure 9. Alzheimer's Disease Blood Diagnostic Report Years Considered
Figure 10. Global Alzheimer's Disease Blood Diagnostic Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 11. Global Alzheimer's Disease Blood Diagnostic Revenue (2020-2031) & (US$ Million)
Figure 12. Global Alzheimer's Disease Blood Diagnostic Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 13. Global Alzheimer's Disease Blood Diagnostic Revenue Market Share by Region (2020-2031)
Figure 14. Global Alzheimer's Disease Blood Diagnostic Revenue Market Share Ranking (2024)
Figure 15. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 16. Amyloid Beta (Aβ) Revenue Market Share by Player in 2024
Figure 17. Tau Proteins Revenue Market Share by Player in 2024
Figure 18. Others Revenue Market Share by Player in 2024
Figure 19. Global Alzheimer's Disease Blood Diagnostic Revenue Market Share by Type (2020-2031)
Figure 20. Global Alzheimer's Disease Blood Diagnostic Revenue Market Share by Application (2020-2031)
Figure 21. North America Alzheimer's Disease Blood Diagnostic Revenue YoY (2020-2031) & (US$ Million)
Figure 22. North America Top 5 Players Alzheimer's Disease Blood Diagnostic Revenue (US$ Million) in 2024
Figure 23. North America Alzheimer's Disease Blood Diagnostic Revenue (US$ Million) by Type (2020 - 2031)
Figure 24. North America Alzheimer's Disease Blood Diagnostic Revenue (US$ Million) by Application (2020-2031)
Figure 25. US Alzheimer's Disease Blood Diagnostic Revenue (2020-2031) & (US$ Million)
Figure 26. Canada Alzheimer's Disease Blood Diagnostic Revenue (2020-2031) & (US$ Million)
Figure 27. Mexico Alzheimer's Disease Blood Diagnostic Revenue (2020-2031) & (US$ Million)
Figure 28. Europe Alzheimer's Disease Blood Diagnostic Revenue YoY (2020-2031) & (US$ Million)
Figure 29. Europe Top 5 Players Alzheimer's Disease Blood Diagnostic Revenue (US$ Million) in 2024
Figure 30. Europe Alzheimer's Disease Blood Diagnostic Revenue (US$ Million) by Type (2020-2031)
Figure 31. Europe Alzheimer's Disease Blood Diagnostic Revenue (US$ Million) by Application (2020-2031)
Figure 32. Germany Alzheimer's Disease Blood Diagnostic Revenue (2020-2031) & (US$ Million)
Figure 33. France Alzheimer's Disease Blood Diagnostic Revenue (2020-2031) & (US$ Million)
Figure 34. U.K. Alzheimer's Disease Blood Diagnostic Revenue (2020-2031) & (US$ Million)
Figure 35. Italy Alzheimer's Disease Blood Diagnostic Revenue (2020-2031) & (US$ Million)
Figure 36. Russia Alzheimer's Disease Blood Diagnostic Revenue (2020-2031) & (US$ Million)
Figure 37. Asia-Pacific Alzheimer's Disease Blood Diagnostic Revenue YoY (2020-2031) & (US$ Million)
Figure 38. Asia-Pacific Top 8 Players Alzheimer's Disease Blood Diagnostic Revenue (US$ Million) in 2024
Figure 39. Asia-Pacific Alzheimer's Disease Blood Diagnostic Revenue (US$ Million) by Type (2020-2031)
Figure 40. Asia-Pacific Alzheimer's Disease Blood Diagnostic Revenue (US$ Million) by Application (2020-2031)
Figure 41. Indonesia Alzheimer's Disease Blood Diagnostic Revenue (2020-2031) & (US$ Million)
Figure 42. Japan Alzheimer's Disease Blood Diagnostic Revenue (2020-2031) & (US$ Million)
Figure 43. South Korea Alzheimer's Disease Blood Diagnostic Revenue (2020-2031) & (US$ Million)
Figure 44. Australia Alzheimer's Disease Blood Diagnostic Revenue (2020-2031) & (US$ Million)
Figure 45. India Alzheimer's Disease Blood Diagnostic Revenue (2020-2031) & (US$ Million)
Figure 46. Indonesia Alzheimer's Disease Blood Diagnostic Revenue (2020-2031) & (US$ Million)
Figure 47. Vietnam Alzheimer's Disease Blood Diagnostic Revenue (2020-2031) & (US$ Million)
Figure 48. Malaysia Alzheimer's Disease Blood Diagnostic Revenue (2020-2031) & (US$ Million)
Figure 49. Philippines Alzheimer's Disease Blood Diagnostic Revenue (2020-2031) & (US$ Million)
Figure 50. Singapore Alzheimer's Disease Blood Diagnostic Revenue (2020-2031) & (US$ Million)
Figure 51. Central and South America Alzheimer's Disease Blood Diagnostic Revenue YoY (2020-2031) & (US$ Million)
Figure 52. Central and South America Top 5 Players Alzheimer's Disease Blood Diagnostic Revenue (US$ Million) in 2024
Figure 53. Central and South America Alzheimer's Disease Blood Diagnostic Revenue (US$ Million) by Type (2020-2031)
Figure 54. Central and South America Alzheimer's Disease Blood Diagnostic Revenue (US$ Million) by Application (2020-2031)
Figure 55. Brazil Alzheimer's Disease Blood Diagnostic Revenue (2020-2025) & (US$ Million)
Figure 56. Argentina Alzheimer's Disease Blood Diagnostic Revenue (2020-2025) & (US$ Million)
Figure 57. Middle East and Africa Alzheimer's Disease Blood Diagnostic Revenue YoY (2020-2031) & (US$ Million)
Figure 58. Middle East and Africa Top 5 Players Alzheimer's Disease Blood Diagnostic Revenue (US$ Million) in 2024
Figure 59. South America Alzheimer's Disease Blood Diagnostic Revenue (US$ Million) by Type (2020-2031)
Figure 60. Middle East and Africa Alzheimer's Disease Blood Diagnostic Revenue (US$ Million) by Application (2020-2031)
Figure 61. GCC Countries Alzheimer's Disease Blood Diagnostic Revenue (2020-2025) & (US$ Million)
Figure 62. Israel Alzheimer's Disease Blood Diagnostic Revenue (2020-2025) & (US$ Million)
Figure 63. Egypt Alzheimer's Disease Blood Diagnostic Revenue (2020-2025) & (US$ Million)
Figure 64. South Africa Alzheimer's Disease Blood Diagnostic Revenue (2020-2025) & (US$ Million)
Figure 65. Alzheimer's Disease Blood Diagnostic Industry Chain Mapping
Figure 66. Channels of Distribution (Direct Vs Distribution)
Figure 67. Bottom-up and Top-down Approaches for This Report
Figure 68. Data Triangulation
Figure 69. Key Executives Interviewed
Table 1. Global Alzheimer's Disease Blood Diagnostic Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Alzheimer's Disease Blood Diagnostic Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Alzheimer's Disease Blood Diagnostic Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Alzheimer's Disease Blood Diagnostic Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Alzheimer's Disease Blood Diagnostic Revenue by Region (2026-2031) & (US$ Million)
Table 6. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 7. Global Alzheimer's Disease Blood Diagnostic Revenue by Players (2020-2025) & (US$ Million)
Table 8. Global Alzheimer's Disease Blood Diagnostic Revenue Market Share by Players (2020-2025)
Table 9. Global Key Players’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 10. Global Alzheimer's Disease Blood Diagnostic by Player Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Alzheimer's Disease Blood Diagnostic as of 2024)
Table 11. Global Alzheimer's Disease Blood Diagnostic Average Gross Margin (%) by Player (2020 VS 2024)
Table 12. Global Alzheimer's Disease Blood Diagnostic Companies Headquarters
Table 13. Global Alzheimer's Disease Blood Diagnostic Market Concentration Ratio (CR5 and HHI)
Table 14. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 15. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 16. Global Alzheimer's Disease Blood Diagnostic Revenue by Type (2020-2025) & (US$ Million)
Table 17. Global Alzheimer's Disease Blood Diagnostic Revenue by Type (2026-2031) & (US$ Million)
Table 18. Key Product Attributes and Differentiation
Table 19. Global Alzheimer's Disease Blood Diagnostic Revenue by Application (2020-2025) & (US$ Million)
Table 20. Global Alzheimer's Disease Blood Diagnostic Revenue by Application (2026-2031) & (US$ Million)
Table 21. Alzheimer's Disease Blood Diagnostic High-Growth Sectors Demand CAGR (2024-2031)
Table 22. Top Customers by Region
Table 23. Top Customers by Application
Table 24. North America Alzheimer's Disease Blood Diagnostic Growth Accelerators and Market Barriers
Table 25. North America Alzheimer's Disease Blood Diagnostic Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 26. Europe Alzheimer's Disease Blood Diagnostic Growth Accelerators and Market Barriers
Table 27. Europe Alzheimer's Disease Blood Diagnostic Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 28. Asia-Pacific Alzheimer's Disease Blood Diagnostic Growth Accelerators and Market Barriers
Table 29. Asia-Pacific Alzheimer's Disease Blood Diagnostic Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 30. Central and South America Alzheimer's Disease Blood Diagnostic Investment Opportunities and Key Challenges
Table 31. Central and South America Alzheimer's Disease Blood Diagnostic Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 32. Middle East and Africa Alzheimer's Disease Blood Diagnostic Investment Opportunities and Key Challenges
Table 33. Middle East and Africa Alzheimer's Disease Blood Diagnostic Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 34. Quanterix Corporation Information
Table 35. Quanterix Description and Major Businesses
Table 36. Quanterix Product Features and Attributes
Table 37. Quanterix Revenue (US$ Million) and Gross Margin (2020-2025)
Table 38. Quanterix Revenue Proportion by Product in 2024
Table 39. Quanterix Revenue Proportion by Application in 2024
Table 40. Quanterix Revenue Proportion by Geographic Area in 2024
Table 41. Quanterix Alzheimer's Disease Blood Diagnostic SWOT Analysis
Table 42. Quanterix Recent Developments
Table 43. C2N Diagnostics Corporation Information
Table 44. C2N Diagnostics Description and Major Businesses
Table 45. C2N Diagnostics Product Features and Attributes
Table 46. C2N Diagnostics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 47. C2N Diagnostics Revenue Proportion by Product in 2024
Table 48. C2N Diagnostics Revenue Proportion by Application in 2024
Table 49. C2N Diagnostics Revenue Proportion by Geographic Area in 2024
Table 50. C2N Diagnostics Alzheimer's Disease Blood Diagnostic SWOT Analysis
Table 51. C2N Diagnostics Recent Developments
Table 52. Sysmex Corporation Information
Table 53. Sysmex Description and Major Businesses
Table 54. Sysmex Product Features and Attributes
Table 55. Sysmex Revenue (US$ Million) and Gross Margin (2020-2025)
Table 56. Sysmex Revenue Proportion by Product in 2024
Table 57. Sysmex Revenue Proportion by Application in 2024
Table 58. Sysmex Revenue Proportion by Geographic Area in 2024
Table 59. Sysmex Alzheimer's Disease Blood Diagnostic SWOT Analysis
Table 60. Sysmex Recent Developments
Table 61. Quest Diagnostics Corporation Information
Table 62. Quest Diagnostics Description and Major Businesses
Table 63. Quest Diagnostics Product Features and Attributes
Table 64. Quest Diagnostics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 65. Quest Diagnostics Revenue Proportion by Product in 2024
Table 66. Quest Diagnostics Revenue Proportion by Application in 2024
Table 67. Quest Diagnostics Revenue Proportion by Geographic Area in 2024
Table 68. Quest Diagnostics Alzheimer's Disease Blood Diagnostic SWOT Analysis
Table 69. Quest Diagnostics Recent Developments
Table 70. Roche Diagnostics Corporation Information
Table 71. Roche Diagnostics Description and Major Businesses
Table 72. Roche Diagnostics Product Features and Attributes
Table 73. Roche Diagnostics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 74. Roche Diagnostics Revenue Proportion by Product in 2024
Table 75. Roche Diagnostics Revenue Proportion by Application in 2024
Table 76. Roche Diagnostics Revenue Proportion by Geographic Area in 2024
Table 77. Roche Diagnostics Alzheimer's Disease Blood Diagnostic SWOT Analysis
Table 78. Roche Diagnostics Recent Developments
Table 79. Eli Lilly and Company Corporation Information
Table 80. Eli Lilly and Company Description and Major Businesses
Table 81. Eli Lilly and Company Product Features and Attributes
Table 82. Eli Lilly and Company Revenue (US$ Million) and Gross Margin (2020-2025)
Table 83. Eli Lilly and Company Recent Developments
Table 84. Fujirebio Corporation Information
Table 85. Fujirebio Description and Major Businesses
Table 86. Fujirebio Product Features and Attributes
Table 87. Fujirebio Revenue (US$ Million) and Gross Margin (2020-2025)
Table 88. Fujirebio Recent Developments
Table 89. Amoneta Diagnostics Corporation Information
Table 90. Amoneta Diagnostics Description and Major Businesses
Table 91. Amoneta Diagnostics Product Features and Attributes
Table 92. Amoneta Diagnostics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 93. Amoneta Diagnostics Recent Developments
Table 94. MagQu Corporation Information
Table 95. MagQu Description and Major Businesses
Table 96. MagQu Product Features and Attributes
Table 97. MagQu Revenue (US$ Million) and Gross Margin (2020-2025)
Table 98. MagQu Recent Developments
Table 99. Vazyme Corporation Information
Table 100. Vazyme Description and Major Businesses
Table 101. Vazyme Product Features and Attributes
Table 102. Vazyme Revenue (US$ Million) and Gross Margin (2020-2025)
Table 103. Vazyme Recent Developments
Table 104. KingMed Diagnostics Corporation Information
Table 105. KingMed Diagnostics Description and Major Businesses
Table 106. KingMed Diagnostics Product Features and Attributes
Table 107. KingMed Diagnostics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 108. KingMed Diagnostics Recent Developments
Table 109. Anqun Bioengineering Corporation Information
Table 110. Anqun Bioengineering Description and Major Businesses
Table 111. Anqun Bioengineering Product Features and Attributes
Table 112. Anqun Bioengineering Revenue (US$ Million) and Gross Margin (2020-2025)
Table 113. Anqun Bioengineering Recent Developments
Table 114. Raw Materials Key Suppliers
Table 115. Distributors List
Table 116. Market Trends and Market Evolution
Table 117. Market Drivers and Opportunities
Table 118. Market Challenges, Risks, and Restraints
Table 119. Research Programs/Design for This Report
Table 120. Key Data Information from Secondary Sources
Table 121. Key Data Information from Primary Sources
List of Figures
Figure 1. Alzheimer's Disease Blood Diagnostic Product Picture
Figure 2. Global Alzheimer's Disease Blood Diagnostic Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Amyloid Beta (Aβ) Product Picture
Figure 4. Tau Proteins Product Picture
Figure 5. Others Product Picture
Figure 6. Global Alzheimer's Disease Blood Diagnostic Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 7. Early Diagnosis
Figure 8. Clinical Research
Figure 9. Alzheimer's Disease Blood Diagnostic Report Years Considered
Figure 10. Global Alzheimer's Disease Blood Diagnostic Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 11. Global Alzheimer's Disease Blood Diagnostic Revenue (2020-2031) & (US$ Million)
Figure 12. Global Alzheimer's Disease Blood Diagnostic Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 13. Global Alzheimer's Disease Blood Diagnostic Revenue Market Share by Region (2020-2031)
Figure 14. Global Alzheimer's Disease Blood Diagnostic Revenue Market Share Ranking (2024)
Figure 15. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 16. Amyloid Beta (Aβ) Revenue Market Share by Player in 2024
Figure 17. Tau Proteins Revenue Market Share by Player in 2024
Figure 18. Others Revenue Market Share by Player in 2024
Figure 19. Global Alzheimer's Disease Blood Diagnostic Revenue Market Share by Type (2020-2031)
Figure 20. Global Alzheimer's Disease Blood Diagnostic Revenue Market Share by Application (2020-2031)
Figure 21. North America Alzheimer's Disease Blood Diagnostic Revenue YoY (2020-2031) & (US$ Million)
Figure 22. North America Top 5 Players Alzheimer's Disease Blood Diagnostic Revenue (US$ Million) in 2024
Figure 23. North America Alzheimer's Disease Blood Diagnostic Revenue (US$ Million) by Type (2020 - 2031)
Figure 24. North America Alzheimer's Disease Blood Diagnostic Revenue (US$ Million) by Application (2020-2031)
Figure 25. US Alzheimer's Disease Blood Diagnostic Revenue (2020-2031) & (US$ Million)
Figure 26. Canada Alzheimer's Disease Blood Diagnostic Revenue (2020-2031) & (US$ Million)
Figure 27. Mexico Alzheimer's Disease Blood Diagnostic Revenue (2020-2031) & (US$ Million)
Figure 28. Europe Alzheimer's Disease Blood Diagnostic Revenue YoY (2020-2031) & (US$ Million)
Figure 29. Europe Top 5 Players Alzheimer's Disease Blood Diagnostic Revenue (US$ Million) in 2024
Figure 30. Europe Alzheimer's Disease Blood Diagnostic Revenue (US$ Million) by Type (2020-2031)
Figure 31. Europe Alzheimer's Disease Blood Diagnostic Revenue (US$ Million) by Application (2020-2031)
Figure 32. Germany Alzheimer's Disease Blood Diagnostic Revenue (2020-2031) & (US$ Million)
Figure 33. France Alzheimer's Disease Blood Diagnostic Revenue (2020-2031) & (US$ Million)
Figure 34. U.K. Alzheimer's Disease Blood Diagnostic Revenue (2020-2031) & (US$ Million)
Figure 35. Italy Alzheimer's Disease Blood Diagnostic Revenue (2020-2031) & (US$ Million)
Figure 36. Russia Alzheimer's Disease Blood Diagnostic Revenue (2020-2031) & (US$ Million)
Figure 37. Asia-Pacific Alzheimer's Disease Blood Diagnostic Revenue YoY (2020-2031) & (US$ Million)
Figure 38. Asia-Pacific Top 8 Players Alzheimer's Disease Blood Diagnostic Revenue (US$ Million) in 2024
Figure 39. Asia-Pacific Alzheimer's Disease Blood Diagnostic Revenue (US$ Million) by Type (2020-2031)
Figure 40. Asia-Pacific Alzheimer's Disease Blood Diagnostic Revenue (US$ Million) by Application (2020-2031)
Figure 41. Indonesia Alzheimer's Disease Blood Diagnostic Revenue (2020-2031) & (US$ Million)
Figure 42. Japan Alzheimer's Disease Blood Diagnostic Revenue (2020-2031) & (US$ Million)
Figure 43. South Korea Alzheimer's Disease Blood Diagnostic Revenue (2020-2031) & (US$ Million)
Figure 44. Australia Alzheimer's Disease Blood Diagnostic Revenue (2020-2031) & (US$ Million)
Figure 45. India Alzheimer's Disease Blood Diagnostic Revenue (2020-2031) & (US$ Million)
Figure 46. Indonesia Alzheimer's Disease Blood Diagnostic Revenue (2020-2031) & (US$ Million)
Figure 47. Vietnam Alzheimer's Disease Blood Diagnostic Revenue (2020-2031) & (US$ Million)
Figure 48. Malaysia Alzheimer's Disease Blood Diagnostic Revenue (2020-2031) & (US$ Million)
Figure 49. Philippines Alzheimer's Disease Blood Diagnostic Revenue (2020-2031) & (US$ Million)
Figure 50. Singapore Alzheimer's Disease Blood Diagnostic Revenue (2020-2031) & (US$ Million)
Figure 51. Central and South America Alzheimer's Disease Blood Diagnostic Revenue YoY (2020-2031) & (US$ Million)
Figure 52. Central and South America Top 5 Players Alzheimer's Disease Blood Diagnostic Revenue (US$ Million) in 2024
Figure 53. Central and South America Alzheimer's Disease Blood Diagnostic Revenue (US$ Million) by Type (2020-2031)
Figure 54. Central and South America Alzheimer's Disease Blood Diagnostic Revenue (US$ Million) by Application (2020-2031)
Figure 55. Brazil Alzheimer's Disease Blood Diagnostic Revenue (2020-2025) & (US$ Million)
Figure 56. Argentina Alzheimer's Disease Blood Diagnostic Revenue (2020-2025) & (US$ Million)
Figure 57. Middle East and Africa Alzheimer's Disease Blood Diagnostic Revenue YoY (2020-2031) & (US$ Million)
Figure 58. Middle East and Africa Top 5 Players Alzheimer's Disease Blood Diagnostic Revenue (US$ Million) in 2024
Figure 59. South America Alzheimer's Disease Blood Diagnostic Revenue (US$ Million) by Type (2020-2031)
Figure 60. Middle East and Africa Alzheimer's Disease Blood Diagnostic Revenue (US$ Million) by Application (2020-2031)
Figure 61. GCC Countries Alzheimer's Disease Blood Diagnostic Revenue (2020-2025) & (US$ Million)
Figure 62. Israel Alzheimer's Disease Blood Diagnostic Revenue (2020-2025) & (US$ Million)
Figure 63. Egypt Alzheimer's Disease Blood Diagnostic Revenue (2020-2025) & (US$ Million)
Figure 64. South Africa Alzheimer's Disease Blood Diagnostic Revenue (2020-2025) & (US$ Million)
Figure 65. Alzheimer's Disease Blood Diagnostic Industry Chain Mapping
Figure 66. Channels of Distribution (Direct Vs Distribution)
Figure 67. Bottom-up and Top-down Approaches for This Report
Figure 68. Data Triangulation
Figure 69. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Smart Grid Digital Substation Market Research Report 2026
Mar 17, 26
Global Photovoltaic Molded Case Circuit Breaker Market Research Report 2026
Mar 17, 26
Global Roll-Roll Automobile Business Market Research Report 2026
Mar 17, 26
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232